Estimating influenza vaccine effectiveness using routine surveillance data among children aged 6-59 months for five consecutive influenza seasons

被引:16
|
作者
Su, Wei-Ju [1 ,2 ,3 ]
Chan, Ta-Chien [4 ]
Chuang, Pei-Hung [5 ]
Liu, Yu-Lun [1 ]
Lee, Ping-Ing [3 ]
Liu, Ming-Tsan [1 ]
Chuang, Jen-Hsiang [1 ,6 ]
机构
[1] Minist Hlth & Welf, Ctr Dis Control, Taipei 10050, Taiwan
[2] Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Taipei 10764, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Pediat, Taipei 10016, Taiwan
[4] Acad Sinica, Res Ctr Humanities & Social Sci, Taipei 115, Taiwan
[5] Taiwan Fdn Poison Control, Taipei, Taiwan
[6] Natl Yang Ming Univ, Inst Hlth Care Adm, Taipei 112, Taiwan
关键词
Influenza vaccine effectiveness; Case-control studies; Influenza surveillance; LABORATORY-CONFIRMED INFLUENZA; IMMUNIZATION PRACTICES ACIP; TEST-NEGATIVE DESIGN; HEALTHY-CHILDREN; ADVISORY-COMMITTEE; TRIVALENT; EFFICACY; VIRUS; HOSPITALIZATIONS; RECOMMENDATIONS;
D O I
10.1016/j.ijid.2014.11.011
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: We aimed to estimate the pooled vaccine effectiveness (VE) in children over five winters through data linkage of two existing surveillance systems. Methods: Five test-negative case-control studies were conducted from November to February during the 2004/2005 to 2008/2009 seasons. Sentinel physicians from the Viral Surveillance Network enrolled children aged 6-59 months with influenza-like illness to collect throat swabs. Through linking with a nationwide vaccination registry, we measured the VE with a logistic regression model adjusting for age, gender, and week of symptom onset. Both fixed-effects and random-effects models were used in the meta-analysis. Results: Four thousand four hundred and ninety-four subjects were included. The proportion of influenza test-positive subjects across the five seasons was 11.5% (132/1151), 7.2% (41/572), 23.9% (189/791), 6.6% (75/1135), and 11.2% (95/845), respectively. The pooled VE was 62% (95% confidence interval (CI) 48-83%) in both meta-analysis models. By age category, VE was 51% (95% CI 23-68%) for those aged 6-23 months and 75% (95% CI 60-84%) for those aged 24-59 months. Conclusions: Influenza vaccination provided measurable protection against laboratory-confirmed influenza among children aged 6-59 months despite variations in the vaccine match during the 2004/2005 to 2008/2009 influenza seasons in Taiwan. (C) 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
引用
收藏
页码:115 / 121
页数:7
相关论文
共 50 条
  • [41] Vaccine Effectiveness Against Influenza Hospitalization and Emergency Department Visits in 2 A(H3N2) Dominant Influenza Seasons Among Children <18 Years Old-New Vaccine Surveillance Network 2016-2017 and 2017-2018
    Kim, Sara S.
    Naioti, Eric A.
    Halasa, Natasha B.
    Stewart, Laura S.
    Williams, John, V
    Michaels, Marian G.
    Selvarangan, Rangaraj
    Harrison, Christopher J.
    Staat, Mary A.
    Schlaudecker, Elizabeth P.
    Weinberg, Geoffrey A.
    Szilagyi, Peter G.
    Boom, Julie A.
    Sahni, Leila C.
    Englund, Janet A.
    Klein, Eileen J.
    Ogokeh, Constance E.
    Campbell, Angela P.
    Patel, Manish M.
    JOURNAL OF INFECTIOUS DISEASES, 2022, 226 (01) : 91 - 96
  • [42] Feasibility of age- and gestation-based routine universal influenza vaccines schedules for children aged 6 months-2 years and pregnant women
    Dang, Sandra T. K. N.
    Cabrera, Romen Rivero
    Yeung, Karene Hoi Ting
    van der Putten, Ingeborg M.
    Nelson, E. Anthony S.
    VACCINE, 2021, 39 (46) : 6754 - 6761
  • [43] Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance network-Pilot case-control studies using different control groups, 2008-2009 season, Spain
    Savulescu, Camelia
    Valenciano, Marta
    de Mateo, Salvador
    Larrauri, Amparo
    VACCINE, 2010, 28 (16) : 2903 - 2907
  • [44] A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months
    Carmona Martinez, Alfonso
    Salamanca de la Cueva, Ignacio
    Boutet, Philippe
    Vanden Abeele, Carline
    Smolenov, Igor
    Devaster, Jeanne-Marie
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (07) : 1959 - 1968
  • [45] The immunogenicity and safety of a single 0.5 mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥6 to <36 months: Data from a randomized, Phase III study
    Esposito, Susanna
    Marchisio, Paola
    Montinaro, Valentina
    Bianchini, Sonia
    Weverling, Gerrit Jan
    Pariani, Elena
    Amendola, Antonella
    Fabiano, Valentina
    Pivetti, Valentina
    Zanetti, Alessandro
    Zuccotti, Gian Vincenzo
    VACCINE, 2012, 30 (49) : 7005 - 7012
  • [46] Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres
    Pepin, Stephanie
    Dupuy, Martin
    Corazon Borja-Tabora, Charissa Fay
    Montellano, May
    Bravo, Lulu
    Santos, Jaime
    de Castro, Jo-Anne
    Rivera-Medina, Doris Maribel
    Cutland, Clare
    Ariza, Miguel
    Diez-Domingo, Javier
    Diaz Gonzalez, Celia
    Martinon-Torres, Federico
    Papadopoulou-Alataki, Efimia
    Theodoriado, Maria
    Kazek-Duret, Marie Pierre
    Gurunathan, Sanjay
    De Bruijn, Iris
    Abalos, Karina
    Aurell, Helena
    Maria Baldo, Jose
    Bona, Gianni
    Angel, Miguel
    Cadorna-Carlos, Josefina
    Cangrejo, Marcela
    Capilna, Brindusa Ruxandra
    Cara, Alexandra Carmen
    Carmona Martinez, Alfonso
    Chemin, Frederic
    Closa, Ricardo
    Cots, Manuel Baca
    Coux, Florence
    Diez-Domingo, Javier
    Dracea, Laura Larisa
    Emporiadou, Maria
    Espiau, Maria
    Esposito, Susanna
    Pecurariu, Oana Asso Falup
    Garces-Sanchez, Maria
    Garg, Sanjay
    Gil, Amparo
    Gonzales, Laurie
    Guevel, Ronan
    Guillen, Sara
    Icardi, Giancarlo
    Laot, Thelma
    Lacroix, Isabelle
    Mares, Josep
    Martinez Pons, Manuel
    Moreau, Catherine
    VACCINE, 2019, 37 (13) : 1876 - 1884
  • [47] Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China
    Hu, Yuemei
    Shao, Ming
    Hu, Yuansheng
    Liang, Qi
    Jia, Ningning
    Chu, Kai
    Xu, Li
    Li, Jing
    Li, Changgui
    Zhu, Fengcai
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2020, 16 (07) : 1691 - 1698
  • [48] Strengths and limitations of assessing influenza vaccine effectiveness using routinely collected, passive surveillance data in Ontario, Canada, 2007 to 2012: balancing efficiency versus quality
    Savage, R. D.
    Winter, A. L.
    Rosella, L. C.
    Olsha, R.
    Gubbay, J. B.
    Skowronski, D. M.
    Crowcroft, N. S.
    EUROSURVEILLANCE, 2015, 20 (16) : 29 - 37
  • [49] Influenza Vaccine Effectiveness Among Patients With Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data From Ontario, Canada
    Blanchette, Phillip S.
    Chung, Hannah
    Pritchard, Kathleen I.
    Earle, Craig C.
    Campitelli, Michael A.
    Buchan, Sarah A.
    Schwartz, Kevin L.
    Crowcroft, Natasha S.
    Gubbay, Jonathan B.
    Karnauchow, Timothy
    Katz, Kevin
    McGeer, Allison J.
    McNally, James D.
    Richardson, David C.
    Richardson, Susan E.
    Rosella, Laura C.
    Simor, Andrew
    Smieja, Marek
    Zahariadis, George
    Campigotto, Aaron
    Kwong, Jeffrey C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2795 - +
  • [50] Higher vaccine effectiveness in seasons with predominant circulation of seasonal influenza A(H1N1) than in A(H3N2) seasons: Test-negative case-control studies using surveillance data, Spain, 2003-2011
    Savulescu, Camelia
    Jimenez-Jorge, Silvia
    Delgado-Sanz, Concha
    de Mateo, Salvador
    Pozo, Francisco
    Casas, Inmaculada
    Larrauri, Amparo
    VACCINE, 2014, 32 (35) : 4404 - 4411